Next Article in Journal
Influence of Fragrances on Human Psychophysiological Activity: With Special Reference to Human Electroencephalographic Response
Previous Article in Journal
Synthesis, Spatial Structure and Analgesic Activity of Sodium 3-Benzylaminocarbonyl-1-methyl-2,2-dioxo-1H-2λ6,1-benzothiazin-4-olate Solvates
Article Menu

Export Article

Open AccessArticle
Sci. Pharm. 2016, 84(4), 715-723;

A Comparative Pharmacokinetics Study of the Anti-Parkinsonian Drug Pramipexole

PT Equilab International Bioavailability and Bioequivalence Laboratory, Jl. RS Fatmawati Persil 33, 12430 Jakarta, Indonesia
Dexa Laboratories of Biomolecular Sciences (DLBS), Industri Selatan V Block PP No. 7, Jababeka Industrial Estate II, Cikarang, 17550 West Java, Indonesia
Author to whom correspondence should be addressed.
Academic Editor: Gernot Eller
Received: 5 September 2016 / Revised: 7 November 2016 / Accepted: 14 November 2016 / Published: 18 November 2016
Full-Text   |   PDF [609 KB, uploaded 18 November 2016]   |  


The present study aimed to compare pharmacokinetic parameters of two pramipexole 0.25 mg formulations in order to show bioequivalence. The study was conducted in a randomized, open-label, two-period, two-sequence, and crossover design, involving 23 healthy volunteers. One of the 0.25 mg formulations of pramipexole evaluated in the study was manufactured by PT Dexa Medica, Palembang, Indonesia, the other, used as the reference, by Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany. All eligible subjects were required to fast before each drug administration period, which was separated by a one-week washout period. Pramipexole concentrations in plasma were assayed using a validated ultra performance liquid chromatography with mass spectrometry (UPLC-MS/MS) detector. The evaluated pharmacokinetic parameters included the area under the plasma concentration curve from time zero to the last observed measurable concentration (AUC0-t), the area under the plasma concentration curve extrapolated to infinite time (AUC0-∞), the maximum plasma concentration (Cmax), the time to reach Cmax (tmax), and the plasma concentration half-life (t1/2). To evaluate the bioequivalence of those two pramipexole formulations, 90% confidence intervals (CIs) for geometric mean ratios of both formulations were calculated for AUC and Cmax parameters, while tmax and t1/2 differences were analyzed on the non-transformed data using Wilcoxon matched-pairs and a Student’s paired t-test, respectively. The 90% CIs for the geometric mean ratios of the two pramipexole formulations were 95.89% (90.73%–101.34%), 95.53% (89.75%–101.68%), and 92.11% (84.35%–100.58%) for AUC0-t, AUC0-∞, and Cmax, respectively. There were no statistically significant differences for tmax and t1/2 between the two pramipexole formulations. It is concluded that two pramipexole formulations in this study were bioequivalent. View Full-Text
Keywords: bioavailability; bioequivalence; Parkinson’s disease; pharmacokinetics; pramipexole bioavailability; bioequivalence; Parkinson’s disease; pharmacokinetics; pramipexole

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Putri, R.S.I.; Setiawati, E.; Aziswan, S.A.; Ong, F.; Tjandrawinata, R.R.; Susanto, L.W. A Comparative Pharmacokinetics Study of the Anti-Parkinsonian Drug Pramipexole. Sci. Pharm. 2016, 84, 715-723.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics



[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top